Hemispherx Announces First Shipment of Rintatolimod (Ampligen®) to Early Access Program in Europe
July 25, 2016 08:30 ET
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, July 25, 2016 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) announced today that the first order of rintatolimod (Ampligen®) for the Early Access Program (EAP) in Europe...
Hemispherx Biopharma: Dr. William M. Mitchell Publishes Article Titled, “Efficacy of Rintatolimod in the Treatment of Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME)” in Expert Review of Clinical Pharmacology
June 07, 2016 08:30 ET
|
AIM ImmunoTech Inc.
PHILADELPHIA, June 07, 2016 (GLOBE NEWSWIRE) -- Dr. William Mitchell, M.D., Ph.D., Chairman of the Board of Directors for Hemispherx Biopharma (NYSE MKT:HEB) and a Professor of Pathology,...
Hemispherx Biopharma Reviews Ampligen® Data With National Institute of Neurological Disorders and Stroke (NINDS)
March 10, 2016 08:30 ET
|
AIM ImmunoTech Inc.
PHILADELPHIA, March 10, 2016 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) (the “Company” or “Hemispherx”) announced that the strong commitment by the National Institutes of Health (NIH)...
Hemispherx Biopharma Receives the European Patent Office Grant of New Composition of Matter Patent Covering Ampligen(R) Formulations
September 28, 2015 08:30 ET
|
AIM ImmunoTech Inc.
PHILADELPHIA, Sept. 28, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), announced that it received formal notice on September 21, 2015, that the...
Hemispherx Biopharma Reports Article by Senior Authors From Italian Ministry of Health and Related Agencies Suggesting Broad Applicability of Ampligen(R) to Multiple Sclerosis
September 23, 2015 08:30 ET
|
AIM ImmunoTech Inc.
PHILADELPHIA, Sept. 23, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) announced today a new peer reviewed article, with senior authors from the Italian Ministry of Health and other...
Hemispherx Biopharma Announces Patient Assistance Program for Chronic Fatigue Syndrome Open Label Study
September 17, 2015 08:30 ET
|
AIM ImmunoTech Inc.
PHILADELPHIA, Sept. 17, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), announced today the approval by the Board of Directors for a Patient...
Hemispherx Biopharma Reports Low NK Cell Activity in Chronic Fatigue Syndrome (CFS) and Relationship to Disease Symptoms
September 15, 2015 08:30 ET
|
AIM ImmunoTech Inc.
PHILADELPHIA, Sept. 15, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) announced today the publication in the current issue of the peer reviewed Journal of Clinical and Cellular...
Photo Release -- Hemispherx Biopharma Posts Photographs of the Ampligen Facility in New Brunswick, New Jersey
August 27, 2015 08:30 ET
|
AIM ImmunoTech Inc.
NEW BRUNSWICK, N.J., Aug. 27, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) recently hosted a Stockholder Open House in their manufacturing facility in New Brunswick, NJ. During the...
Hemispherx Receives the European Patent Office Examining Division's Notice of Intention to Grant the New Composition of Matter Patent Covering Ampligen(R) Formulations
June 25, 2015 08:30 ET
|
AIM ImmunoTech Inc.
PHILADELPHIA, June 25, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE:HEB) (the "Company" or "Hemispherx"), announced that it received formal notice on June 18, 2015, that the European...
Hemispherx Biopharma Europe N.V./S.A.: Orphan Medicine Designation and European Medicines Agency Public Opinion Summary Published by EMA Regarding Ampligen/Rintatolimod for Ebola Virus Disease (EVD)
May 26, 2015 12:46 ET
|
AIM ImmunoTech Inc.
PHILADELPHIA, May 26, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx") announces that the European Medicines Agency (EMA) has published on May 22,...